Pituitary adenoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}} {{AE}} {{AAM}} | {{CMG}} {{AE}} {{AAM}} | ||
==Overview== | ==Overview== | ||
Pharmacologic medical therapy is recommended among patients with [[prolactinoma]], [[thyrotrophic]], [[somatotrophic]] and adrenocorticotropic adenomas. | Pharmacologic medical therapy is recommended among patients with [[prolactinoma]], [[thyrotrophic]], [[somatotrophic]], and [[adrenocorticotrophic hormone|adrenocorticotropic]] adenomas. | ||
==Medical Therapy== | ==Medical Therapy== | ||
Treatment options depend on the type of tumor and on its size: | Treatment options depend on the type of [[tumor]] and on its size: | ||
* '''Prolactinomas''' are most often treated with [[bromocriptine]] | * '''Prolactinomas''' are most often treated with [[dopamine agonists]] such as [[bromocriptine]] and [[cabergoline]]. The latter, decreases [[tumor]] size as well as alleviates [[symptoms]]. [[Dopamine agonist|Dopamine agonists]] are followed by serial imaging to detect the recurrence. If the adenoma is large, treatment may include [[radiation therapy]] and [[surgery]]. Efforts have been made to use a [[progesterone]] [[antagonist]] for the treatment of prolactinomas, but so far have not proved successful. | ||
* '''Thyrotrophic adenomas''' respond to [[Somatostatin|octreotide, a long-acting somatostatin analog]], in many but not all cases according to a review of the medical literature. Unlike prolactinomas, thyrotrophic adenomas characteristically respond poorly to dopamine agonist treatment. | * '''Thyrotrophic adenomas''' respond to [[Somatostatin|octreotide, a long-acting somatostatin analog]], in many but not all cases according to a review of the medical literature. Unlike [[prolactinomas]], thyrotrophic adenomas characteristically respond poorly to [[dopamine agonist]] treatment. | ||
*'''Somatotrophic adenomas''' can be treated with somatostatin analogues, dopamine analogues, and the newer GH-receptor antagonists, such as [[pegvisomant]]. | *'''Somatotrophic adenomas''' can be treated with [[Octreotide|somatostatin analogues]], dopamine analogues, and the newer GH-receptor antagonists, such as [[pegvisomant]]. | ||
*''' Adrenocorticotropic adenomas''' can be treated with [[ketoconazole]], an inhibitor of [[steroidogenesis]], it's considered as a drug of choice in adjunctive medical therapy for ACTH-producing adenomas. | *''' Adrenocorticotropic adenomas''' can be treated with [[ketoconazole]], an inhibitor of [[steroidogenesis]], it's considered as a drug of choice in adjunctive medical therapy for [[Adrenocorticotropic hormone|ACTH]]-producing adenomas. | ||
*[[Clomifene]] is contraindicated in patient with | *'''Recurrent macroadenoma''' can be treated with [[octreotide]], a long-acting somatostatin analogue. This can result in both reduction of the size of the [[tumour]] and reduction in the [[serum]] levels of [[growth hormone]].<ref name="Radiopaedia"> Dr Amir Rezaee and Dr Yuranga Weerakkody http://radiopaedia.org/articles/pituitary-adenoma 2015. URL accessed on 9 30 2015</ref> | ||
*[[Clomifene]] is contraindicated in patient with pituitary adenoma. | |||
==References== | ==References== | ||
| Line 17: | Line 19: | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Mature chapter]] | [[Category:Mature chapter]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Neurology]] | |||
[[Category:Neurosurgery]] | |||
[[Category:Endocrinology]] | |||
Latest revision as of 19:56, 2 October 2019
|
Pituitary adenoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pituitary adenoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Pituitary adenoma medical therapy |
|
Risk calculators and risk factors for Pituitary adenoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]
Overview
Pharmacologic medical therapy is recommended among patients with prolactinoma, thyrotrophic, somatotrophic, and adrenocorticotropic adenomas.
Medical Therapy
Treatment options depend on the type of tumor and on its size:
- Prolactinomas are most often treated with dopamine agonists such as bromocriptine and cabergoline. The latter, decreases tumor size as well as alleviates symptoms. Dopamine agonists are followed by serial imaging to detect the recurrence. If the adenoma is large, treatment may include radiation therapy and surgery. Efforts have been made to use a progesterone antagonist for the treatment of prolactinomas, but so far have not proved successful.
- Thyrotrophic adenomas respond to octreotide, a long-acting somatostatin analog, in many but not all cases according to a review of the medical literature. Unlike prolactinomas, thyrotrophic adenomas characteristically respond poorly to dopamine agonist treatment.
- Somatotrophic adenomas can be treated with somatostatin analogues, dopamine analogues, and the newer GH-receptor antagonists, such as pegvisomant.
- Adrenocorticotropic adenomas can be treated with ketoconazole, an inhibitor of steroidogenesis, it's considered as a drug of choice in adjunctive medical therapy for ACTH-producing adenomas.
- Recurrent macroadenoma can be treated with octreotide, a long-acting somatostatin analogue. This can result in both reduction of the size of the tumour and reduction in the serum levels of growth hormone.[1]
- Clomifene is contraindicated in patient with pituitary adenoma.
References
- ↑ Dr Amir Rezaee and Dr Yuranga Weerakkody http://radiopaedia.org/articles/pituitary-adenoma 2015. URL accessed on 9 30 2015